The decision is the latest sign that federal health officials want more research on medical marijuana as its use grows.
OG Article: here
View our Fair Use Policy: here
FDA Approves Groundbreaking Study on Marijuana for PTSD
Federal health officials have authorized a clinical trial to study marijuana’s efficacy in treating PTSD among military veterans. The decision marks a significant shift in the FDA’s stance, as it is one of the few instances where the agency has approved smoking marijuana to explore its therapeutic benefits rather than its harms.
The Study at a Glance
Sponsor: Multidisciplinary Association for Psychedelic Studies (MAPS), led by Rick Doblin
Funding: A $12.9 million grant from Michigan's cannabis regulatory agency.
Participants: 320 military veterans, making it one of the largest studies of its kind.
Methodology: Use of high-potency marijuana sourced from Canada, reflecting the types of cannabis patients use in real-world settings.
Focus: Smoking cannabis, the most common consumption method, due to its rapid onset of effects—a crucial factor for PTSD management.
This trial contrasts with a smaller 2018 study, which found no significant benefit of cannabis over a placebo. However, the earlier study used government-provided marijuana criticized for its low potency and quality.
Federal Shifts in Cannabis Research
Historically, federal marijuana research focused on its harms, and regulatory hurdles hindered studies on therapeutic benefits. However, changing public sentiment and legalization trends have prompted a gradual shift:
Public Support: 39 states now allow medical marijuana, and 24 permit recreational use.
Policy Changes: The Biden administration has proposed downgrading cannabis from Schedule I, which currently classifies it as having no medical value and high abuse potential.
Funding and Focus: Agencies like the Department of Health and Human Services have acknowledged the need for more rigorous cannabis studies to assess its therapeutic and non-therapeutic risks.
Mixed Reactions from Experts
Support for the Study
Many researchers and veterans advocate for exploring cannabis as a treatment option:
Veteran Perspective: Gary Hess, a Marine veteran, credits marijuana with alleviating debilitating PTSD symptoms, improving essential functions like sleep, digestion, and emotional regulation.
Potential Benefits: Dr. Lynnette Averill of Baylor College of Medicine believes cannabis could be a valuable tool, given the widespread need for new PTSD treatments.
Skepticism and Concerns
Others caution against prematurely endorsing cannabis for PTSD treatment:
Addiction Risks: The American Psychiatric Association warns that marijuana can worsen mental health conditions and lead to dependency.
Insufficient Evidence: Dr. Harold Kudler, a former VA researcher, remains doubtful of marijuana’s efficacy based on existing studies.
Ethical Concerns: Critics like Kevin Sabet of Smart Approaches to Marijuana question the use of smoking in the study, given the availability of alternative delivery methods.
Implications for Veterans and PTSD Treatment
Cannabis use among veterans has surged, with many seeking relief outside traditional medical systems. While the Department of Veterans Affairs allows clinicians to discuss cannabis use, they cannot recommend or facilitate medical marijuana access—a policy that frustrates many veteran groups.
This study could provide critical data to address gaps in understanding marijuana’s impact on PTSD. For veterans and researchers alike, the FDA’s decision represents a cautious but promising step forward in exploring cannabis as a potential therapeutic option.
The results of this trial could significantly influence future cannabis policy, treatment guidelines, and the broader understanding of marijuana's medical applications.
Comments